Replimune Capital Surpluse vs Capital Stock Analysis
REPL Stock | USD 7.90 0.79 11.11% |
Replimune financial indicator trend analysis is much more than just breaking down Replimune Group prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Replimune Group is a good investment. Please check the relationship between Replimune Capital Surpluse and its Capital Stock accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Capital Surpluse vs Capital Stock
Capital Surpluse vs Capital Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Replimune Group Capital Surpluse account and Capital Stock. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Replimune's Capital Surpluse and Capital Stock is 0.94. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Capital Stock in the same time period over historical financial statements of Replimune Group, assuming nothing else is changed. The correlation between historical values of Replimune's Capital Surpluse and Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Replimune Group are associated (or correlated) with its Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Stock has no effect on the direction of Capital Surpluse i.e., Replimune's Capital Surpluse and Capital Stock go up and down completely randomly.
Correlation Coefficient | 0.94 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Capital Surpluse
Capital Stock
The total amount of a company’s capital funded by shareholders through the issue and subscription of shares.Most indicators from Replimune's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Replimune Group current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. At this time, Replimune's Selling General Administrative is quite stable compared to the past year. Enterprise Value is expected to rise to about 527.2 M this year, although the value of Tax Provision will most likely fall to about 255.2 K.
2023 | 2024 (projected) | Depreciation And Amortization | 2.7M | 1.4M | Interest Income | 580.8K | 935.8K |
Replimune fundamental ratios Correlations
Click cells to compare fundamentals
Replimune Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Replimune fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 234.1M | 543.1M | 461.2M | 646.6M | 487.7M | 359.6M | |
Other Current Liab | 303K | 514K | 1.3M | 3.0M | 3.3M | 2.2M | |
Total Current Liabilities | 11.9M | 14.5M | 20.8M | 33.8M | 40.4M | 42.5M | |
Total Stockholder Equity | 183.7M | 498.7M | 411.2M | 555.3M | 374.5M | 291.7M | |
Net Tangible Assets | 137.9M | 183.7M | 498.7M | 411.2M | 472.9M | 496.6M | |
Property Plant And Equipment Net | 58.2M | 57.7M | 55.6M | 52.4M | 52.4M | 39.7M | |
Net Debt | (17.7M) | (149.2M) | (73.1M) | (85.8M) | 1.4M | 1.5M | |
Retained Earnings | (112.3M) | (193.2M) | (311.2M) | (485.5M) | (701.3M) | (666.2M) | |
Accounts Payable | 3.4M | 2.4M | 3.7M | 5.4M | 2.6M | 3.7M | |
Cash | 59.5M | 182.5M | 105.9M | 146.6M | 74.5M | 87.0M | |
Non Current Assets Total | 59.8M | 59.4M | 57.2M | 54.0M | 54.1M | 41.1M | |
Cash And Short Term Investments | 168.6M | 476.3M | 395.7M | 583.4M | 420.7M | 311.0M | |
Net Receivables | 3.0M | 3.0M | 3.1M | 2.9M | 4.9M | 3.2M | |
Common Stock Total Equity | 24K | 32K | 37K | 47K | 54.1K | 31.9K | |
Common Stock Shares Outstanding | 34.3M | 46.2M | 52.2M | 58.2M | 66.6M | 47.1M | |
Short Term Investments | 109.1M | 293.8M | 289.7M | 436.8M | 346.2M | 223.9M | |
Liabilities And Stockholders Equity | 234.1M | 543.1M | 461.2M | 646.6M | 487.7M | 359.6M | |
Non Current Liabilities Total | 38.5M | 29.8M | 29.2M | 57.5M | 72.8M | 48.8M | |
Capital Surpluse | 1.1M | 198.6M | 297.0M | 692.2M | 796.1M | 835.9M | |
Other Current Assets | 2.7M | 4.5M | 5.3M | 6.3M | 8.1M | 4.4M | |
Other Stockholder Equity | 297.0M | 692.2M | 723.4M | 1.0B | 1.1B | 552.5M | |
Total Liab | 50.4M | 44.4M | 50.0M | 91.3M | 113.2M | 67.8M | |
Property Plant And Equipment Gross | 58.2M | 57.7M | 60.4M | 59.6M | 62.3M | 42.8M | |
Total Current Assets | 174.3M | 483.7M | 404.0M | 592.6M | 433.7M | 318.5M | |
Accumulated Other Comprehensive Income | (982K) | (394K) | (973K) | 5.7M | 4.9M | 5.1M | |
Common Stock | 32K | 37K | 47K | 57K | 61K | 40.0K | |
Property Plant Equipment | 12.2M | 58.2M | 7.4M | 55.6M | 63.9M | 67.1M | |
Net Invested Capital | 193.5M | 498.7M | 411.2M | 583.9M | 419.3M | 362.1M | |
Net Working Capital | 162.4M | 469.2M | 383.2M | 558.8M | 393.2M | 339.0M | |
Short Long Term Debt Total | 41.8M | 33.3M | 32.8M | 60.8M | 75.9M | 46.0M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Replimune Group using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Additional Information and Resources on Investing in Replimune Stock
When determining whether Replimune Group is a strong investment it is important to analyze Replimune's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Replimune's future performance. For an informed investment choice regarding Replimune Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.24) | Return On Assets (0.26) | Return On Equity (0.46) |
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.